Cardiovascular Risk Differs for Stone Formers With ESKD
Among patients with nephrolithiasis or urolithiasis, the cardiovascular event rate was 74.4 per 1000 person-years.
Among patients with nephrolithiasis or urolithiasis, the cardiovascular event rate was 74.4 per 1000 person-years.
Tiopronin is indicated for the prevention of cystine stone formation in patients with severe homozygous cystinuria who are unresponsive to treatment with high fluid intake, alkali, and diet modification.
The risk for a first-time symptomatic kidney stone begins to increase in the second trimester and peaks 0 to 3 months after delivery, a study found.
Urologist-gained renal access for percutaneous nephrolithotomy is associated with significantly lower 90-day rates of hospital readmission and blood transfusion compared with radiologist-gained access, a study found.
More than 450 medical device reports of patient infections, potential contamination recorded from Jan. 1, 2017, to Feb. 20, 2021
Oral sodium bicarbonate therapy given to patients with chronic kidney disease increases urinary pH but also increases urinary citrate levels, which may mitigate the risk for calcium phosphate stone formation.
Kidney stones were associated with different degrees of risk for ischemic than hemorrhagic stroke, according to a recent meta-analysis.
Bone loss in patients with kidney stone disease, particularly in men, has been underappreciated in clinical practice, according to investigators.
Patients with kidney stones who visited both a nephrologist and a urologist had a 6.6-fold higher likelihood of receiving testing for primary hyperparathyroidism, according to a study of veterans.
Tolvaptan improves the urinary lithogenic risk profile of patients with autosomal dominant polycystic kidney disease, according to researchers.